Showing 1691-1700 of 5643 results for "".
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- Survey: 80% of Consumers Would Be More Likely To Visit a Doctor if They Could See the Exact Out-of-Pocket Cost On Their Smartphonehttps://modernod.com/news/survey-80-of-consumers-would-be-more-likely-to-visit-a-doctor-if-they-could-see-the-exact-out-of-pocket-cost-on-their-smartphone/2476190/Metova, a provider of mobile, connected car, connected home and IoT Solutions, announced findings from a “Mobile First” survey on health care and technology, revealing the sentiment of over 1,000 consumers who currently have health care. The survey was conducted to research the growin
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Bausch + Lomb to Acquire Xiidra from Novartishttps://modernod.com/news/bausch-lomb-will-acquire-xiidra/2481704/Bausch + Lomb announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5%. Xiidra is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DE
- Outlook Therapeutics Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-phase-3-norse-two-trial-of-lytenava-for-wet-amd/2479428/Outlook Therapeutics announced positive clinical and highly statistically significant topline results from its pivotal phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010/Lytenava (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). “We are de
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o
- Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartishttps://modernod.com/news/oculis-in-licenses-phase-2-topical-anti-tnf-alpha-antibody-from-novartis/2476220/Oculis has entered into an agreement to in-license a novel topical anti-TNF alpha antibody from Novartis. Terms of the deal were not disclosed. The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically de